Lean Mass Ingredients & Drug Interactions
What is this page for?
First and foremost: checking Lean Mass against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
Lean Mass is a dietary supplement by RS Formulations with 2 active ingredients. Its ingredients are commonly taken for muscle building, athletic performance, fat loss / body recomposition.Based on those ingredients, 611 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are ((2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide). Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against Lean Mass by RS Formulations
Ask about any prescription or over-the-counter medication and we check it for interactions with Lean Mass by RS Formulations — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of Lean Mass by RS Formulations
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Low disclosure
Lean Mass contains 2 active ingredients: ostarine (a SARM being studied for muscle and bone health) and -3-Epihydroxyetioallocholan-17-One. The product also includes gelatin and rice flour as inactive ingredients to form the capsule and provide structure.
Does it work?
Insufficient evidence
The evidence we hold does not establish effectiveness for any claimed use. Ostarine has insufficient reliable evidence to rate for athletic performance, breast cancer, cachexia (severe muscle wasting), muscular dystrophy, or sarcopenia (age-related muscle loss).
No effectiveness data is on file for the other active ingredient.
How safe is it?
Well-documented data
Ostarine is an unapproved investigational drug with documented safety risks and no FDA approval — that's a core concern here. The most common side effects reported are abdominal pain, loss of appetite, constipation, diarrhea, and nausea.
In clinical trials, some patients (ranging from 4% to 21% depending on dose) showed temporary increases in liver enzymes (ALT), a sign of liver stress; in rare cases, liver damage can occur. A small number of trial participants also showed anemia (low red blood cells) and thrombocytopenia (low platelets).
Ostarine affects hormone pathways, so it must be avoided in pregnancy, and there is no safety data for breastfeeding — avoid it then as well.
Meds to double-check
Moderate interaction found
Before taking this product, check any hepatotoxic drugs (medications that can damage the liver), drugs that speed liver metabolism like rifampin, probenecid, and any CYP3A4 inhibitors or CYP2C9 substrates you may be on. These interactions are documented at Moderate or Minor severity.
The bottom line
Scorecard at a glanceFormula with limited ingredient disclosure with insufficient evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.
Lean Mass contains ostarine, an unapproved experimental drug with real safety risks and no proven benefit at established doses. If you take any prescription medication — especially those affecting the liver or metabolized through liver pathways — you need to check it here first.
Talk to your pharmacist or doctor before considering this product; the safety and effectiveness profile does not support routine use.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 1 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 25, 2020.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about Lean Mass, straight from the product label.
| Brand | RS Formulations |
|---|---|
| Net contents | 60 Capsule(s) |
| Market status | On market |
| Date entered into DSLD | Jan 25, 2020 |
| DSLD ID | 211554 |
| Product type | Non-nutrient/non-botanical |
| Supplement form | Capsule |
| Dietary claims / uses | No Claim |
| Intended target group(s) | Adult (18 - 50 Years) |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for Lean Mass by RS Formulations, sourced from the NIH Dietary Supplement Label Database.
Supplement Facts
| Ingredient | Amount | % DV |
|---|---|---|
| SARM/Andro Blend | 65 mg | -- |
| -3-Epihydroxyetioallocholan-17-One | 0 NP | -- |
| ((2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide) | 0 NP | -- |
Other ingredients: Gelatin, Rice Flour
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation
Shred the size Strength, no bloat Anabolic stimulator
FDA Statement of Identity
Dietary Supplement
Suggested/Recommended/Usage/Directions
Recommended Use: Take one capsule in the morning and one capsule in the evening.
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
Lean Mass by RS Formulations label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in Lean Mass by RS Formulations
These are the 2 active ingredients this product is made of. Select any to open its full monograph.
Serving size1 Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.
Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.
SARM/Andro Blend
- › -3-Epihydroxyetioallocholan-17-One
- › ((2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide)
Other (inactive) ingredients: Gelatin, Rice Flour. These complete the product’s ingredient list but are not active constituents.
Lean Mass by RS Formulations Drug Interactions
HelloPharmacist Interaction Report
Lean Mass by RS Formulations contains ostarine, a SARM (selective androgen receptor modulator) that's not FDA-approved and carries documented interaction risks.
The most serious concern is with hepatotoxic drugs (drugs that can damage the liver) — ostarine itself can raise liver enzyme markers in some people, and combining it with other liver-damaging medications could increase that risk further.
Read the full breakdown — every affected drug type, severity by severity
Ostarine also has Moderate interactions with drugs that speed up liver metabolism (CYP3A4 inducers like rifampin), which may weaken ostarine's effects, and with probenecid, which can raise ostarine levels and side effects. It has Minor interactions with drugs that slow liver metabolism (CYP3A4 inhibitors) and with certain blood-pressure or clotting medications metabolized through a different liver pathway (CYP2C9 substrates).
One ingredient in this product, -3-Epihydroxyetioallocholan-17-One, we could not check for interactions. Altogether, these interactions span 593 individual medications.
Before taking Lean Mass, run your exact prescriptions through the medication checker on this page.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against Lean Mass?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in Lean Mass interact with 611 drugs. Click any drug to see the details.
1 of the 2 ingredients in Lean Mass interact with drugs. Each result below shows which ingredient is responsible. ((2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide)
EthionamideTrecator SC
How Ethionamide interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Ethionamide interactionEthosuximideZarontin
How Ethosuximide interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inducers Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Ethosuximide interactionEthynodiol Diacetate, MestranolOvulen
How Ethynodiol Diacetate, Mestranol interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Ethynodiol Diacetate, Mestranol interactionEtrasimodVelsipity
How Etrasimod interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs, Cytochrome P450 2c9 (cyp2c9) Substrates Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Etrasimod interactionEtravirineIntelence
How Etravirine interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 2c9 (cyp2c9) Substrates, Cytochrome P450 3a4 (cyp3a4) Inducers Moderate
Interaction Summary
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Etravirine interactionEzetimibe, AtorvastatinLiptruzet
How Ezetimibe, Atorvastatin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Ezetimibe, Atorvastatin interactionFebuxostatUloric
How Febuxostat interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Febuxostat interactionFedratinib HydrochlorideInrebic
How Fedratinib Hydrochloride interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fedratinib Hydrochloride interactionFelbamateFelbatol
How Felbamate interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Felbamate interactionFenofibrateAntara, Fenofibrate, Lipidil EZ, Lipidil Micro, Lipidil Supra, Lofibra +2 more
How Fenofibrate interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fenofibrate interactionFezolinetantVeozah
How Fezolinetant interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fezolinetant interactionFingolimodGilenya, Tascenso ODT
How Fingolimod interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fingolimod interactionFlucloxacillinStaphylex
How Flucloxacillin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Flucloxacillin interactionFluconazoleDiflucan, Diflucan Injection
How Fluconazole interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inhibitors, Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inhibitors could increase the effects and adverse effects of ostarine, although this is unlikely to be clinically significant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fluconazole interactionFluvastatinLescol, Lescol XL
How Fluvastatin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 2c9 (cyp2c9) Substrates, Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fluvastatin interactionFosaprepitantEmend Injection, Focinvez
How Fosaprepitant interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inhibitors, Cytochrome P450 3a4 (cyp3a4) Inducers Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inhibitors could increase the effects and adverse effects of ostarine, although this is unlikely to be clinically significant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fosaprepitant interactionFosphenytoinCerebyx
How Fosphenytoin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 2c9 (cyp2c9) Substrates, Cytochrome P450 3a4 (cyp3a4) Inducers +1 Moderate
Interaction Summary
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fosphenytoin interactionFosphenytoin SodiumSesquient
How Fosphenytoin Sodium interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inducers, Hepatotoxic Drugs +1 Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fosphenytoin Sodium interactionFostamatinibTavalisse
How Fostamatinib interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fostamatinib interactionFruquintinibFruzaqla
How Fruquintinib interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Fruquintinib interactionGatifloxacinTequin, Tequin Injection
How Gatifloxacin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Gatifloxacin interactionGefitinibIressa
How Gefitinib interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Gefitinib interactionGemcitabineGemzar
How Gemcitabine interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Gemcitabine interactionGemfibrozilLopid
How Gemfibrozil interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Gemfibrozil interactionGivosiran SodiumGivlaari
How Givosiran Sodium interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Givosiran Sodium interactionGliclazideDiamicron
How Gliclazide interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 2c9 (cyp2c9) Substrates, Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Gliclazide interactionGlutethimideDoriden
How Glutethimide interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inducers Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Glutethimide interactionGlyburideAlbert Glyburide, Diabeta, Glycron, Glynase, Glynase PresTab, Micronase +1 more
How Glyburide interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 2c9 (cyp2c9) Substrates, Hepatotoxic Drugs Moderate
Interaction Summary
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Glyburide interactionGlyburide, MetforminGlucovance
How Glyburide, Metformin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Hepatotoxic Drugs, Cytochrome P450 2c9 (cyp2c9) Substrates Moderate
Interaction Summary
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Glyburide, Metformin interactionGriseofulvinFulvicin PG, Fulvicin-U/F, Grisactin, Grisactin Ultra
How Griseofulvin interacts with Lean Mass — through 1 ingredient. Tap an ingredient for the detail:
((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)Cytochrome P450 3a4 (cyp3a4) Inducers Moderate
Interaction Summary
Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Read the full ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) + Griseofulvin interactionEach ingredient & the kinds of drugs it affects
For each ingredient in Lean Mass with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.
((2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide)
Cytochrome P450 3A4 (Cyp3A4) Inducers
Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Ostarine is partially metabolized by CYP3A4. Clinical research shows that taking rifampin, a potent inducer of CYP3A4, reduces the maximum plasma concentration of ostarine by 23% and the area under the curve by 43%.
Hepatotoxic Drugs
Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Some clinical research shows that ostarine can increase alanine aminotransferase, a marker of liver damage, in some patients. Additionally, the U.S. Food and Drug Administration warns that supplements containing SARMs, such as ostarine, have been associated with reports of liver toxicity and there are at least two reports of drug-induced liver injury attributed to the use of ostarine.
Probenecid (Benemid)
Theoretically, concomitant use of ostarine with probenecid could increase the effects and adverse effects of ostarine.
Clinical research shows that probenecid increases ostarine levels and slows the clearance of ostarine, likely via inhibition of UDP-glucuronosyltransferase (UGT). Ostarine is partially metabolized by UGT.
Rifampin (Rifadin)
Theoretically, concomitant use of ostarine with rifampin could decrease the clinical effects of ostarine.
Clinical research shows that taking rifampin with ostarine reduces the maximum plasma concentration of ostarine by 23% and the area under the curve by 43%. Ostarine is partially metabolized by cytochrome P450 3A4 (CYP3A4), and rifampin is a potent CYP3A4 inducer.
Cytochrome P450 2C9 (Cyp2C9) Substrates
Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Although in vitro research suggests that ostarine inhibits CYP2C9, more robust clinical research shows that ostarine does not significantly affect CYP2C9.
Cytochrome P450 3A4 (Cyp3A4) Inhibitors
Theoretically, concomitant use of ostarine with CYP3A4 inhibitors could increase the effects and adverse effects of ostarine, although this is unlikely to be clinically significant.
Ostarine is partially metabolized by CYP3A4. However, clinical research shows that taking itraconazole, a potent inhibitor of CYP3A4, had minimal effects on the levels of ostarine in the body.
Brand information
Manufacturer and brand details for Lean Mass, from the product label.
Lean Mass by RS Formulations: Common Questions
Does Lean Mass by RS Formulations interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
Is ostarine approved by the FDA?
What are the most common side effects?
Can I take this if I'm pregnant or breastfeeding?
Does this product actually work for muscle gain?
What is a SARM?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if Lean Mass is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind Lean Mass’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Sources & How We Checked
Lean Mass's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 10 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Ostarine 10 references
- Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
- Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
- Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
- Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45. PubMed
- Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II tri
- Coss CC, Jones A, Dalton JT. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024 (enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs 2016;34(4):458-67. PubMed
- FDA. FDA Warns against using SARMs in body building products. October 2017. Available at: https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm583021.htm.
- Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518. PubMed
- Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- d) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516
- Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022;13(5):244-248. PubMed
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC